CLPT ClearPoint Neuro
- 5.870
- +0.350+6.34%
- 6.050
- +0.180+3.07%
ClearPoint Neuro News
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory
Clinical Laserthermia Systems (CLS-B.ST) partner ClearPoint Neuro received 510(k) approval from the US Food and Drug Administration for its Prism Bone Anchor Accessory. The approval is expected to hel
ClearPoint Gets FDA Clearance For Neurosurgical Equipment
ClearPoint Neuro (CLPT) said Monday it received 510(k) approval from the US Food and Drug Administration for its Prism Bone Anchor Accessory. The Prism Bone Anchor Accessory is designed for use with s
Express News | Clearpoint Neuro Inc - Plan to Begin Limited Market Release on Schedule in Q2, With a Full Market Release in Second Half of 2024
Express News | ClearPoint Neuro Received FDA Clearance For Prism Bone Anchor Accessory
Express News | Clearpoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
Express News | Clearpoint Neuro Announces Initiation of Limited Market Release for the Smartframe or™ Stereotactic System
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and
ClearPoint Neuro Poised for Growth: Strong Buy Rating Justified Amidst Market Dip
Is There Now An Opportunity In ClearPoint Neuro, Inc. (NASDAQ:CLPT)?
Express News | Clearpoint Neuro Congratulates Its Partner Aviadobio on First Patient Treated in Its Aspire-Ftd Clinical Trial Evaluating Avb-101 for Frontotemporal Dementia With Grn Mutations
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Call Transcript
Here's What Analysts Are Forecasting For ClearPoint Neuro, Inc. (NASDAQ:CLPT) After Its Full-Year Results
Shareholders of ClearPoint Neuro, Inc. (NASDAQ:CLPT) will be pleased this week, given that the stock price is up 19% to US$7.21 following its latest full-year results. Revenues came in at US$24
Express News | ClearPoint Neuro Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Stifel Reiterated a Buy Rating on the Stock and Raised Its Price Target From $8 to $9
ClearPoint Neuro's (CLPT) Strategic Milestones and Market Performance
ClearPoint Neuro, Inc. (NASDAQ: CLPT) shares maintained stability during the preceding session, concluding at $6.05, with a modest uptick of 0.33%. This steadiness in CLPT stock price followed the release of its quarterly financial outcomes. ClearPoint Neuro (CLPT) unveiled its financial performance for the fourth quarter and full fiscal year ending on December 31, 2023. ...
Express News | Stifel Reiterates Buy on ClearPoint Neuro, Raises Price Target to $9
ClearPoint Neuro Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 37.83% Stifel $8 → $9 Reiterates Buy → Buy 10/24/2023 22.51% Stifel → $8 Initiates Coverage On
Earnings Call Summary | ClearPoint Neuro(CLPT.US) Q4 2023 Earnings Conference
The following is a summary of the ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript:Financial Performance:ClearPoint Neuro ended 2023 with $23.1 million in cash, which will be bolstered b
Express News | ClearPoint Neuro Reaffirms 2024 Revenue Guidance Of $28M-$32M, Est $30.433M
ClearPoint Neuro: Q4 Earnings Insights
ClearPoint Neuro (NASDAQ:CLPT) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsClearPoint Neuro beat estimated
Analysis
Price Target
No Data
